Factor IX, along with a large cofactor protein, factor VIII, is involved in the middle phase ofthe blood coagulation cascade (1) . A deficiency of factor IX causes an abnormal bleeding disorder called hemophilia B. The molecular mechanism underlying hemophilia B is very heterogeneous (2) . The human factor IX gene, which has been completely sequenced, is located at the Xq27 region and is expressed in hepatocytes with high tissue specificity (3, 4) . At present, little is known about the mechanism responsible for the developmental regulation of the factor IX gene. Normally, factor IX gene expression increases during the perinatal stage and reaches its subadult level in a few weeks after birth (5-7). The factor IX genes of the hemophilia B Leyden trait, however, do not express until the onset of puberty (8, 9) . After onset of puberty, the factor IX level in the peripheral blood of patients with this phenotype gradually rises to a subnormal or normal level at a rate of -5% per year. Recently, the specific molecular defects in five known factor IX Leyden genes have been reported (10) (11) (12) (13) . However, no evidence of any direct correlation between the mutations and functional defects of these genes has been analyzed.
In the present report, we analyze the structure of a hemophilia B Leyden gene. ¶ Experimental evidence correlates the defects found in the 5'-untranslated sequence of factor IX Leyden genes and regulation of these genes. We also describe specific protein binding to the region. was obtained from Perkin-Elmer/Cetus. The Mutagene in vitro mutagenesis kit was obtained from Bio-Rad. p-Galactosidase expression plasmid vector (pCH110) and acetyl-CoA were obtained from Pharmacia P-L Biochemical. The ELISA amplification system was purchased from Bethesda Research Laboratories. Synthetic oligonucleotides were obtained from the Center for Molecular Genetics core facility on the Michigan campus. pUMSVOCAT is a low-background expression vector with the chloramphenicol acetyltransferase (CAT) gene (14) . Human androgen receptor cDNA and pD5 (an expression vector with adenovirus major late promoter) were provided by C. Chang (University of Chicago) and K. Berkner (Zymogenetics), respectively. pD5hAR, an androgen receptor-expressing vector, was constructed by inserting the human androgen receptor cDNA into pD5.
MATERIALS AND METHODS
Hemophilia B Leyden Family. A young male family member (now 6 years old) was first referred to the Portland Hemophilia Center for an abnormal bleeding episode when he was circumcised at the age of 15 days; at this time he received a blood transfusion. Five months later, his factor IX activity level was determined at 5% normal, whereas his factor VIII:C level was normal. At 1 year, his factor IX activity level was also 5% normal. Since then he has been rather mildly affected, and no factor IX concentrate infusion has been required after the first bleeding episode. His factor IX activity level had slightly increased to 10% when he was recently assayed (December 13, 1989) at the same hemophilia center. One of his uncles also had similar abnormal bleeding when he was circumcised and had shown a mild bleeding tendency until pubertal stage, but this bleeding has since ameliorated. Five more distant, maternal, male relatives have had similar bleeding tendencies. Blood samples (10-20 ml) were freshly drawn into a 0.1 vol of 3.8% sodium citrate after written consent from these individuals of the hemophilia B family. The samples were centrifuged for 10 min at 3000 rpm to separate plasma and cell fractions. The plasma fraction was used for determining factor IX activity by a one-stage clotting assay with human factor IX-deficient plasma and antigen levels by a Laurel rocket immunoelectrophoresis method by employing polyclonal factor IX antibodies (Wisconsin Blood Center, Milwaukee). The antigen level reproducibly detected by this method was >6% normal control. The factor IX antigen level of the affected member and his mother were also determined by ELISA assays in our laboratory by using the polyclonal antibodies and ELISA amplification system (BRL). The lowest antigen level reproducibly detected by this assay was -1% normal control. Pooled plasma of 30 normal healthy individuals was used as control for these assays. Cell fractions were used to prepare total genomic DNA by the Triton X-100 method (15 and guanine present at position -6. The segregation of the single-base mutation, G-IA at position -6, agrees well with plasma data (Fig. lA) . All coding regions of factor IX and the splicing junctions as well as the 5'-end flanking region to nt -1244 were analyzed in 111-4 (affected member). The mutation found in this family may be from a C-*T change at the CpG sequence on the complementary strand. The base change, incidentally, resulted in loss ofa Taq I site in the normal gene. This gene was also found to have the codon for threonine at the third position of its activation peptide, a known dimorphic residue, and a 1.8-kilobase (kb) Taq I polymorphic fragment (3) . In this study, we also corrected our original sequence reported for the normal gene as follows: nt -1096, adenine; nt -597, cytosine; nt -598, thymine; and nt -423, cytosine. The transcription starting site of the gene was recently determined to be at nt -150 (4), placing the region containing the mutation in the 5'-untranslated sequence of the gene and close to the translation start site. The site of the mutation was found to be in a small general region where all other specific mutations (T-EA substitution at -20, G-*C substitution at -6, a base deletion or A-GG substitution at +13) were identified in all five known families affected with this phenotype (10-13). We designate this general region of -40 bp in length the Leyden-specific region (LS region). Prepubertal members of families carrying mutations at nt + 13 and -20 were severely to moderately affected (10, 11, 13) . It is interesting to note that the family carrying a G-C mutation at nt -6 is rather severely affected (M. Vidaud, personal communication). A mutation of A-+G at nt + 13 in an unrelated hemophilia B patient was also reported (22) . No additional family information of this patient, however, is available at present, but it is highly likely that this family is also affected with hemophilia B Leyden. These data strongly suggest that the LS region is involved in the developmental regulation of this gene because the chance of all unrelated Leyden families having random mutation in the LS region is extremely small.
We then carried out a series of functional assays to test the importance of the LS region in the regulation of this gene by using expression vectors derived from pUMSVOCAT (14) and HepG2 cells, which can express vitamin K-dependent proteins, including factor IX (23) . The DNA fragments used in constructing these vectors contained the factor IX sequence spanning nt +4 to -416 as well as nt +29 to -416. In a recent gene dissection analysis, we demonstrated that fundamental cis-acting elements required for factor IX gene expression are contained within this immediate 5'-upstream region of the gene (4). In these vectors, the CAT gene was ligated to the 5'-end sequence of factor IX gene with or without the specific single-base changes at nt -20 (T-EA) or nt -6 (G-IA). Table 1 shows that these constructs were then used for expression in the human hepatoma cell line. Mutations at either nt -6 or nt -20 lowered the expression level to about one-third that of control. Although the mutations did not totally eliminate the expression, the decreases in CAT expression activity seen in the cultured cell system are very significant. The mutation at nt -20 consistently gave somewhat lower CAT activities compared with the mutation (G-IA) at nt -6, which may, in part, reflect the difference in severity of symptoms. Whether the reduced activities are due to the effects of the mutations on the transcriptional level or on the translational level is yet undetermined.
Drastic decreases in expression activity were also seen when deletions were extended beyond position -3 toward the 5'-upstream region (Fig. 2) . In this experiment, the residual activities, 26.1%, 16.7%, and 14.9o, were found for p-416/-13CAT, p-416/-23CAT, and p-416/-5OCAT, respectively. These results indicate that the specific region encompassing nt -20 to -6 of the 5' half of the LS region has an important role in the regulation of factor IX gene expression, whereas the role of the 3' half of the LS region containing the +13 position is not clear at present. These data further support the hypothesis that the LS region is involved in the regulation of the factor IX gene. These data also suggest the possibility of an additional, yet-unidentified element(s) that may be involved in regulation. Table 2 shows that expression levels of the mutant factor IX gene sequences generally increased with androgen in a concentration-dependent manner. Androgen, however, also elevated expression of the normal control similarly. These results strongly suggest that induction of factor IX synthesis at the onset of puberty in hemophilia B Leyden patients is probably from the indirect, but not the direct, effects of testosterone on factor IX biosynthesis. A set of genes from hepatocytes may be more directly affected by testosterone, and products ofthese genes singly or collectively may induce expression ofthe factor IX Leyden gene but not ofthe normal factor IX gene. The mechanism of this effect, which is highly likely to involve the LS region of the gene, has yet to be determined.
Testosterone given in therapy increased factor IX activity in hemophilia B Leyden patients (24) . This effect, however, appears more general and not specific for the factor IX Leyden gene because similar effects were also seen for other proteins, such as factor VIII (25) (26) (27) . Our results obtained from the in vitro assay system agree well with this observation. Interestingly, sequence (GGTACAACTAATCG) significantly similar to a glucocorticoid responsive element is located between nt -20 and -6. Such sequences are responsive to various hormones, including androgens, glucocorticoids, and progesterones in mouse mammary tumor virus (28). In our assay system, however, neither dexamethasone nor estrogen significantly changed expression of the CAT vectors used (data not shown). Gel-retardation assays using the entire 420-bp sequence spanning nt +4 to -416 of the 5' end of the factor IX gene showed three major retarded bands with a few minor bands (Fig. 3) . When a double-stranded oligonucleotide (40 bp in size) corresponding to nt -32 to +8 was used as a competitor (Fig. 4) , the top two retarded bands (a and b) specifically disappeared, indicating that these proteins bind to the region containing the specific mutations. This intepretation was further supported in our recent observation that two oligonucleotide subsets (20 bp and 16 bp in sizes) that specifically cover the -20 region or the -6 region, respectively, also bound proteins (unpublished data). Binding of these proteins, designated LSP-1 and LSP-2, to the LS region of the gene may be important in regulating factor IX synthesis. These proteins may also bind to the LS region offactor IX mRNAs, affecting their processing, stability, or even its elongation. Recently, the tat protein of human immunodeficiency virus type 1 was reported to trans-activate the virus gene tran- 10, 11, 13) , including a G--A change at nt -6 found in this study, are shown with small arrows. (-) at nt +13 indicates a base deletion. Our original numbering system (3) was used. According to the revised transcription start site that corresponds to nt -150 in the original numbering system (4), the LS region is contained in the 5'-untranslated region. Pairs of arrows facing each other as well as the thick arrow with two arrowheads show the location of pallindromic sequences. A tandem repeat of two regions (nt -31 through -6 and nt -5 through +21) is noted (11) . Hatched bar region (40 bp) corresponds to the synthetic oligonucleotide used as specific DNA competitor in the gel-retardation assay (Fig. 3). scription through a nascent RNA target (29, 30) . Ironresponsive elements were also found in the 5'-untranslated region of human ferritin mRNA (31) .
Various secondary structures are often found in regulatory elements of genes (32) . The LS region has interesting palindromic structures as well as repeats (Fig. 4) . These particular structures, although rather short, may be involved in binding of these protein factors. Although the role of the 3' half of the LS region is not clear at present, a fair tandem repeat of region -31 through -6 and region -5 through +21 (10) may support the possibility that the region containing nt +13 is also involved in regulating this gene through mechanisms yet unknown. The role of the region containing nt +13 in the regulation of this gene could be secondary to the region containing nt -20 and -6 or any other unidentified region(s). If so, the subtle defective effect of the mutations at nt + 13 on expression may not be easily detected in the assay system used in our study.
Most mammalian genes are developmentally regulated. Among them, developmental regulation of the expression of hemoglobin genes (33), a-fetoprotein, as well as albumin have been extensively studied (34) . Establishment of the structural and functional importance of LS region for regulating expression of factor IX gene will facilitate further studies on the developmental regulation ofthis gene in in vivo assay models, such as transgenic animals.
Note Added in Proof. Recently we observed that point mutations at + 13 (G or base deletion) also lower the expression activity of p-416/29 (+13:G) or p-416/29 (+13:del) to 26% of that of p-416/29 (normal control). The data, together with those in Fig. 2 , suggest a possibility that the 5' and 3' halves of the LS-region may not function cooperatively. Also, to observe the effect of mutations, the intact sequences surrounding +13 are required.
